MASI Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets non invasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Company profile

Joseph Kiani
Fiscal year end
IRS number

MASI stock data



23 Feb 21
13 Apr 21
2 Jan 22
Quarter (USD)
Jan 21 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Jan 21 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Masimo earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 645M 645M 645M 645M 645M 645M
Cash burn (monthly) 9.15M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 30.82M n/a n/a n/a n/a n/a
Cash remaining 614.18M n/a n/a n/a n/a n/a
Runway (months of cash) 67.2 n/a n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
8 Apr 21 Young Micah W Common Stock Sell Dispose S No Yes 239 2,087 498.79K 14,593
8 Apr 21 Young Micah W Common Stock Option exercise Aquire M No No 86.95 2,087 181.46K 16,680
8 Apr 21 Young Micah W NQSO Common Stock Option exercise Dispose M No No 86.95 2,087 181.46K 4,175
26 Feb 21 Young Micah W NQSO Common Stock Grant Aquire A No No 250.73 3,956 991.89K 3,956
26 Feb 21 Sampath Anand NQSO Common Stock Grant Aquire A No No 250.73 2,637 661.18K 2,637
26 Feb 21 John Todd Koning NQSO Common Stock Grant Aquire A No No 250.73 1,483 371.83K 1,483
26 Feb 21 Muhsin Bilal NQSO Common Stock Grant Aquire A No No 250.73 7,912 1.98M 7,912

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

82.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 475 453 +4.9%
Opened positions 71 56 +26.8%
Closed positions 49 69 -29.0%
Increased positions 177 154 +14.9%
Reduced positions 144 167 -13.8%
13F shares
Current Prev Q Change
Total value 12.22B 10.49B +16.5%
Total shares 45.53M 44.47M +2.4%
Total puts 54.9K 144.5K -62.0%
Total calls 135.5K 290.1K -53.3%
Total put/call ratio 0.4 0.5 -18.7%
Largest owners
Shares Value Change
BLK Blackrock 8.32M $2.23B +5.3%
Vanguard 4.6M $1.23B +2.3%
FMR 3.83M $1.03B -13.9%
Ownership Capital B.V. 1.73M $465.37M +28.2%
STT State Street 1.67M $447.4M +1.3%
IVZ Invesco 1.49M $400.8M +6.3%
Massachusetts Financial Services 1M $269.12M -2.9%
BK Bank Of New York Mellon 847.21K $227.37M +0.8%
Champlain Investment Partners 837.3K $224.72M +14.9%
CS Credit Suisse 769.88K $206.62M +7.8%
Largest transactions
Shares Bought/sold Change
FMR 3.83M -618.38K -13.9%
Norges Bank 451.94K +451.94K NEW
BLK Blackrock 8.32M +418.29K +5.3%
American Century Companies 30.06K -404.48K -93.1%
Wellington Management 298.64K -398.29K -57.1%
Ownership Capital B.V. 1.73M +381.66K +28.2%
Carillon Tower Advisers 366.24K +304.43K +492.6%
Victory Capital Management 519.03K -253.15K -32.8%
APG Asset Management 276.15K +178.41K +182.5%
MCS Martin Currie 487.87K +174.06K +55.5%

Financial report summary

  • Summary of Material Risk Factors
  • Risks Related to Our Revenues
  • Some of our products are in development or have been recently introduced into the market and may not achieve market acceptance, which could limit our growth and adversely affect our business, financial condition and results of operations.
  • We face competition from other companies, many of which have substantially greater resources than we do. If we do not successfully develop and commercialize enhanced or new products that remain competitive with products or alternative technologies developed by others, we could lose revenue opportunities and customers, and our ability to grow our business would be impaired, adversely affecting our financial condition and results of operations.
  • We depend on our domestic and international OEM partners for a portion of our revenue. If they do not devote sufficient resources to the promotion of products that use our technologies, our business would be harmed.
  • If we fail to maintain or develop relationships with GPOs, sales of our products would decline.
  • Inadequate levels of coverage or reimbursement from governmental or other third-party payers for our products, or for procedures using our products, may cause our revenue to decline or prevent us from realizing revenues from future products.
  • Consolidation in the healthcare industry could lead to demands for price concessions or to the exclusion of existing market participants from certain markets, which could have an adverse effect on our business, results of operations or financial condition.
  • Our customers may reduce, delay or cancel purchases due to a variety of factors, such as lower hospital census levels or third-party guidelines, which could adversely affect our business, financial condition and results of operations.
  • The loss of any large customer or distributor, or any cancellation or delay of a significant purchase by a large customer, could reduce our net sales and harm our operating results.
  • Counterfeit Masimo sensors and third-party medical device reprocessors that reprocess our single-patient-use sensors may harm our reputation. Also, these counterfeit and third-party reprocessed sensors, as well as genuine Masimo reprocessed sensors, are sold at lower prices than new Masimo sensors and could cause our revenue to decline, which may adversely affect our business, financial condition and results of operations.
  • Risks Related to Our Intellectual Property
  • If the patents we own or license, or our other intellectual property rights, do not adequately protect our technologies, we may lose market share to our competitors and be unable to operate our business profitably.
  • If third parties claim that we infringe their intellectual property rights, we may incur liabilities and costs and may have to redesign or discontinue selling certain products.
  • We believe competitors may currently be violating and may in the future violate our intellectual property rights. As a result, we may initiate litigation to protect and enforce our intellectual property rights, which may result in substantial expense and may divert management’s attention from implementing our business strategy.
  • Risks Related to Our Regulatory Environment
  • Our failure to obtain and maintain FDA clearances or approvals on a timely basis, or at all, would prevent us from commercializing our current, upgraded or new products in the U.S., which could severely harm our business.
  • The failure of our OEM partners to obtain required FDA clearances or approvals for products that incorporate our technologies could have a negative impact on our revenue.
  • If we or our suppliers fail to comply with ongoing regulatory requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market.
  • Failure to obtain regulatory authorizations in foreign jurisdictions may prevent us from marketing our products abroad.
  • Modifications to our marketed devices may require new regulatory clearances or premarket approvals, or may require us to cease marketing or to recall the modified devices until clearances or approvals are obtained.
  • Regulatory reforms may impact our ability to develop and commercialize our products and technologies.
  • If our products cause or contribute to a death or serious injury, or malfunction in a way that would likely cause or contribute to a death or serious injury, we will be subject to medical device reporting regulations, and may need to initiate voluntary corrective actions such as the recall of our products.
  • Promotion of our products using claims that are off-label, unsubstantiated, false or misleading could subject us to substantial penalties.
  • The regulatory environment governing information, cybersecurity and privacy laws is increasingly demanding and continues to evolve.
  • We may be subject to or otherwise affected by federal and state healthcare laws, including fraud and abuse laws, and could face substantial penalties if we are unable to fully comply with these laws.
  • Legislative and regulatory changes in the healthcare industry could have a negative impact on our financial performance. Furthermore, our business, financial condition, results of operations and cash flows could be significantly and adversely affected by healthcare reform legislation in the U.S. or in our key international markets.
  • Risks Related to Our Business and Operations
  • Our business, financial condition and results of operations may be adversely affected by the COVID-19 pandemic.
  • If our essential employees who are unable to telework become ill or otherwise incapacitated, our operations may be adversely impacted.
  • We may experience conflicts of interest with Cercacor with respect to business opportunities and other matters.
  • Rights provided to Cercacor in the Cross-Licensing Agreement may impede a change in control of our company.
  • Future strategic initiatives, including acquisitions of businesses and strategic investments, could negatively affect our business, financial condition and results of operations if we fail to integrate the acquired businesses successfully into our existing operations or achieve the desired results of our investment.
  • Our credit agreement contains certain covenants and restrictions that may limit our flexibility in operating our business.
  • Risks Related to Our Stock
  • Concentration of ownership of our stock among our existing directors, executive officers and principal stockholders may prevent new investors from influencing significant corporate decisions.
  • Our corporate documents and Delaware law contain provisions that could discourage, delay or prevent a change in control of our company, prevent attempts to replace or remove current management and reduce the market price of our stock.
  • Our bylaws provide that the state or federal courts located within the State of Delaware are the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
  • The laws of foreign countries may not adequately protect our intellectual property rights.
  • We may experience significant fluctuations in our periodic financial results and may not maintain our current levels of profitability in the future.
  • Future changes in accounting pronouncements and tax laws, or the interpretation thereof, could have a significant impact on our reported results, and may affect our historical reporting of previous transactions.
  • If we lose the services of our key personnel, or if we are unable to attract and retain other key personnel, we may not be able to manage our operations or meet our growth objectives.
  • We are involved, and may become involved in the future, in disputes and other legal or regulatory proceedings that, if adversely decided or settled, could materially and adversely affect our business, financial condition and results of operations.
  • Changes to government immigration regulations may materially affect our workforce and limit our supply of qualified professionals, or increase our cost of securing workers.
  • The risks inherent in operating internationally, including the purchase, sale and shipment of our components and products across international borders, may adversely impact our business, financial condition and results of operations.
  • Our operations may be adversely impacted by our exposure to risks related to foreign currency exchange rates.
  • We currently manufacture our products at a limited number of locations and any disruption to, expansion of, or changes in trade programs related to such manufacturing operations could adversely affect our business, financial condition and results of operations.
  • If we do not accurately forecast customer demand, we may hold suboptimal inventory levels that could adversely affect our business, financial condition and results of operations.
  • If we fail to comply with the reporting obligations of the Securities Exchange Act of 1934, as amended, or if we fail to maintain adequate internal control over financial reporting, our business, results of operations and financial condition and investors’ confidence in us could be adversely affected.
  • Changing laws and increasingly complex corporate governance and public disclosure requirements could have an adverse effect on our business and operating results.
  • If product liability claims are brought against us, we could face substantial liability and costs.
  • We may incur environmental and personal injury liabilities related to certain hazardous materials used in our operations.
  • We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.
  • Discontinuation, reform or replacement of LIBOR and other benchmark rates, or uncertainty related to the potential for any of the foregoing, may adversely affect our business.
  • Our stock price may be volatile, and your investment in our stock could suffer a decline in value.
  • Our investors could experience substantial dilution of their investments as a result of subsequent exercises of our outstanding options, vesting of outstanding restricted stock units (RSUs) and performance stock units (PSUs), or the grant of future equity awards by us.
  • Future resales of our stock, including those by our insiders and a few investment funds, may cause our stock price to decline.
Content analysis
H.S. sophomore Avg
New words: acquiree, addiction, afterload, air, amazing, andAlternate, audiovisual, AX, Blueprint, Bridge, bridging, Britain, carryover, Centroid, closure, constant, deoxyhemoglobin, disallowance, disinfection, distancing, door, England, epidemic, exciting, extraordinary, factory, fall, familiarize, faster, female, fever, film, fueled, gathering, globe, halting, heard, hemodynamic, humidified, hypercapnic, hypoxemic, incapacitated, infection, Inline, Inter, interbank, inventorship, Ireland, iXBRL, koning, Labour, leader, LiDCO, Lira, LMMV, loved, male, mandatorily, mandatory, media, mediation, MHLW, Minded, Ministry, modular, naltrexone, nerve, Neuchatel, neuromodulation, newly, nondeductible, nonessential, older, oral, organizational, orientation, Overnight, oxyhemoglobin, pace, pandemic, percutaneously, pertinent, pneumatic, posture, precautionary, preload, prescription, probe, prolonged, prompt, quarantine, quiet, reciprocated, redeemable, relaxation, reopening, reorganization, resistance, retract, risky, Safer, sanitation, science, Scotland, situation, sleep, SOFR, softFlow, somatic, stability, stable, stake, stimulator, stockpiling, stroke, struggle, student, succeed, summarized, surfaced, surge, survey, talent, tapering, TCJA, telework, tenure, thermometer, thermometry, thin, threat, TNI, todd, tool, Turkish, UKCA, unredacted, VSM, wake, Watch, women, workplace, Wuhan
Removed: addressed, age, aim, analyzed, appealed, barker, build, carrier, clarification, compute, conducting, contemplated, Danderyd, david, Discovery, disfavor, drafting, ecosystem, education, eliminate, encouraged, excise, exempted, INDEPENDENCE, insignificant, mail, MINE, print, ramshorst, ratified, repatriation, role, SAB, steven, Sudan, supporting, Sweden, Syria, telephone, terrorism, unite, UNRESOLVED, van